Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-25T18:37:59.673Z Has data issue: false hasContentIssue false
  • English
  • Français

1736 – Long-acting Injectable Risperidone And Oral Antipsychotics In Patients With Schizophrenia - a Prospective One-year Non-interventional Study (inors)

Published online by Cambridge University Press:  15 April 2020

A. Schreiner ,
A. Svensson ,
R. Wapenaar ,
P. Cherubin ,
P. Princet ,
L. Serazetdinova ,
N. Starostina  and
M. Zink
A. Schreiner
Affiliation:
EMEA Medical Affairs, Janssen-Cilag Medical Affairs EMEA, Neuss, Germany
A. Svensson
Affiliation:
EMEA Medical Affairs, Janssen-Cilag AB, Sollentuna, Sweden
R. Wapenaar
Affiliation:
Biostatistics & Programming, Janssen Cilag B.V., Tilburg, The Netherlands
P. Cherubin
Affiliation:
EMEA Medical Affairs, Janssen Cilag France, Issy-les-Moulineaux
P. Princet
Affiliation:
Centre Hospitalier Spéchialisé de Fains-Véel, Fains-Véel, France
L. Serazetdinova
Affiliation:
Federal Institution of Healthcare Psychoneurologic Dispensary No.5, Saint Petersburg
N. Starostina
Affiliation:
Federal Institution of Healthcare Psychiatric Hospital No.2, Nizhni Novgorod, Russia
M. Zink
Affiliation:
Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie, Mannheim, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction and objectives

To explore safety, tolerability, treatment response and hospitalizations in adult patients with schizophrenia treated with long-acting injectable risperidone (RLAI) or oral antipsychotic standard of care (oAP) in routine clinical practice.

Methods

Prospective one-year open-label non-interventional study exploring flexible doses of RLAI and oAPs. Primary outcome was the number of hospitalizations from baseline to endpoint. Additional outcomes were changes in the Clinical Global Impression of Schizophrenia (CGI-SCH), patient functioning (Global Assessment of Functioning) and treatmentemergent adverse events (TEAEs).

Results

The intent-to-treat analysis included 561 patients on RLAI and 522 patients on oAPs (44% female gender, mean age (±SD) 42.2±13.1 years). Demographics and baseline characteristics were comparable, yet RLAI-treated patients had higher disease severity, lower baseline functioning and more substance abuse. The number of hospitalizations did not differ between the two groups while median duration of hospitalization was significantly shorter with RLAI (12.3 vs 20.6 days). Positive, negative, cognitive symptoms, disease severity, patient functioning and medication satisfaction improved significantly better with RLAI than oAPs. The most frequently reported TEAEs (=2% in any group) for RLAI and oral APs were increase of body weight (5.0%; 5.6%), psychotic disorder (2.7%; 4.0%), schizophrenia (2.5%; 3.1%), anxiety (2.3%; 2.7%), insomnia (0.9%; 3.1%) and somnolence (0.4%; 2.5%), respectively.

Conclusion

This one-year non-interventional study supports results of recent randomized controlled trials that treatment with RLAI is associated with less days spent in hospital, better symptomatic and functional outcomes and higher patient satisfaction with medication compared to oral APs.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E1004
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.